MA35125B1 - Alpha glucosidase acide modifiee a traitement accelere - Google Patents
Alpha glucosidase acide modifiee a traitement accelereInfo
- Publication number
- MA35125B1 MA35125B1 MA36431A MA36431A MA35125B1 MA 35125 B1 MA35125 B1 MA 35125B1 MA 36431 A MA36431 A MA 36431A MA 36431 A MA36431 A MA 36431A MA 35125 B1 MA35125 B1 MA 35125B1
- Authority
- MA
- Morocco
- Prior art keywords
- alpha acid
- accelerated treatment
- acid glucosidase
- modified
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/0102—Alpha-glucosidase (3.2.1.20)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161478336P | 2011-04-22 | 2011-04-22 | |
| PCT/US2012/034479 WO2012145644A1 (en) | 2011-04-22 | 2012-04-20 | Modified acid alpha glucosidase with accelerated processing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA35125B1 true MA35125B1 (fr) | 2014-05-02 |
Family
ID=46000406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA36431A MA35125B1 (fr) | 2011-04-22 | 2013-11-14 | Alpha glucosidase acide modifiee a traitement accelere |
Country Status (24)
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014130723A1 (en) | 2013-02-20 | 2014-08-28 | Valerion Therapeutics, Llc | Methods and compositions for treatment of pompe disease |
| CA2961762C (en) | 2014-09-30 | 2024-03-05 | Amicus Therapeutics, Inc. | Highly potent acid alpha-glucosidase with enhanced carbohydrates |
| JP2018538008A (ja) | 2015-11-06 | 2018-12-27 | バイオマリン ファーマシューティカル インコーポレイテッド | リソソーム酵素の取り込みを中和する抗体または他の因子の検出のための細胞ベースアッセイ |
| MY198085A (en) * | 2015-12-30 | 2023-07-31 | Amicus Therapeutics Inc | Augmented acid alpha-glucosidase for the treatment of pompe disease |
| US10227577B2 (en) * | 2016-03-30 | 2019-03-12 | Amicus Therapeutics, Inc. | Method for selection of high M6P recombinant proteins |
| KR102618519B1 (ko) | 2016-03-30 | 2023-12-28 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 재조합 산 알파-글루코시다제를 포함하는 제형 |
| EP3293203A1 (en) | 2016-09-12 | 2018-03-14 | Genethon | Acid-alpha glucosidase variants and uses thereof |
| EP3293260A1 (en) | 2016-09-12 | 2018-03-14 | Genethon | Acid-alpha glucosidase variants and uses thereof |
| EP3293259A1 (en) | 2016-09-12 | 2018-03-14 | Genethon | Acid-alpha glucosidase variants and uses thereof |
| AU2017322376B2 (en) | 2016-09-12 | 2023-08-17 | Association Institut De Myologie | Acid-alpha glucosidase variants and uses thereof |
| HRP20230576T1 (hr) | 2017-05-15 | 2023-09-01 | Amicus Therapeutics, Inc. | Rekombinantna ljudska kisela alfa-glukozidaza |
| MY198804A (en) | 2017-06-07 | 2023-09-28 | Regeneron Pharma | Compositions and methods for internalizing enzymes |
| KR101942093B1 (ko) * | 2018-01-05 | 2019-01-24 | 인하대학교 산학협력단 | 만노시다제 억제제를 포함하는 고만노즈 타입 n-당쇄를 갖는 인간 리소좀 효소 생산용 조성물 |
| BR112020016005A2 (pt) | 2018-02-07 | 2020-12-15 | Regeneron Pharmaceuticals, Inc. | Método de administração de uma proteína terapêutica ao sistema nervoso central, proteína terapêutica multidomínio, polinucleotídeo, vetor de terapia gênica, e, uso de um nucleotídeo que codifica a proteína terapêutica multidomínio |
| CN112135624B (zh) | 2018-05-17 | 2024-07-19 | 瑞泽恩制药公司 | 抗cd63抗体、缀合物和其用途 |
| US20220331408A1 (en) | 2019-07-09 | 2022-10-20 | Genethon | Treatment of glycogen storage disease (gsd) |
| AU2020388634A1 (en) * | 2019-11-19 | 2022-06-23 | AskBio Inc. | Therapeutic adeno-associated virus comprising liver-specific promoters for treating Pompe disease and lysosomal disorders |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6071890A (en) | 1994-12-09 | 2000-06-06 | Genzyme Corporation | Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy |
| US5952516A (en) | 1997-05-08 | 1999-09-14 | Genzyme Corporation | Cationic amphiphiles containing multiplesteroid lipophilic groups |
| WO2000009153A1 (en) | 1997-10-29 | 2000-02-24 | Genzyme Corporation | Compositions and methods for treating lysosomal storage disease |
| US6287857B1 (en) | 1998-02-09 | 2001-09-11 | Genzyme Corporation | Nucleic acid delivery vehicles |
| GB9807464D0 (en) * | 1998-04-07 | 1998-06-10 | Pharming Bv | Purification of human acid µ-glucosidase |
| EP2020438B1 (en) | 1998-12-07 | 2018-04-11 | Genzyme Corporation | Treatment of pompe's disease |
| US7138262B1 (en) | 2000-08-18 | 2006-11-21 | Shire Human Genetic Therapies, Inc. | High mannose proteins and methods of making high mannose proteins |
| US7001994B2 (en) | 2001-01-18 | 2006-02-21 | Genzyme Corporation | Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins |
| US7723296B2 (en) | 2001-01-18 | 2010-05-25 | Genzyme Corporation | Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof |
| JP4742191B2 (ja) * | 2001-06-14 | 2011-08-10 | 独立行政法人産業技術総合研究所 | 糖蛋白質およびその製造方法 |
| BR122015016313B8 (pt) | 2001-07-16 | 2021-05-25 | Genzyme Corp | composto semelhante à ceramida e método de preparar um composto |
| AU2002348261A1 (en) | 2001-11-26 | 2003-06-10 | Genzyme Corporation | Diastereoselective synthesis of udp-glucose : n-acylsphingosine glucosyltransferase inhibitors |
| US6916802B2 (en) | 2002-04-29 | 2005-07-12 | Genzyme Corporation | Amino ceramide-like compounds and therapeutic methods of use |
| ES2371913T3 (es) * | 2003-01-22 | 2012-01-11 | Duke University | Constructos mejorados para expresar polipéptidos lisosomales. |
| US20100196345A1 (en) | 2003-04-27 | 2010-08-05 | Protalix | Production of high mannose proteins in plant culture |
| US7423135B2 (en) | 2003-06-24 | 2008-09-09 | Genzyme Corporation | β-actin and rpS21 promoters and uses thereof |
| AU2005212435B2 (en) | 2004-02-10 | 2010-09-09 | Biomarin Pharmaceutical Inc. | Acid alpha-glucosidase and fragments thereof |
| CA2669347A1 (en) * | 2006-11-13 | 2008-05-29 | Zystor Therapeutics, Inc. | Methods for treating pompe disease |
| HUE044381T2 (hu) | 2008-12-16 | 2019-10-28 | Genzyme Corp | Szintetikus intermedierek oligoszacharid-fehérje konjugátumok elõállításához |
| US8466340B2 (en) * | 2009-02-18 | 2013-06-18 | Amicus Therapeutics, Inc. | Mouse model for pompe disease and methods of use thereof |
-
2012
- 2012-04-20 JP JP2014506579A patent/JP2014513952A/ja active Pending
- 2012-04-20 PE PE2013002377A patent/PE20140617A1/es not_active Application Discontinuation
- 2012-04-20 BR BR112013026976A patent/BR112013026976A2/pt not_active IP Right Cessation
- 2012-04-20 CN CN201280030662.2A patent/CN103797115A/zh active Pending
- 2012-04-20 SG SG2013076526A patent/SG194486A1/en unknown
- 2012-04-20 RU RU2013151875/10A patent/RU2013151875A/ru not_active Application Discontinuation
- 2012-04-20 SG SG10201605874TA patent/SG10201605874TA/en unknown
- 2012-04-20 PH PH1/2013/502149A patent/PH12013502149A1/en unknown
- 2012-04-20 CA CA2833371A patent/CA2833371A1/en not_active Abandoned
- 2012-04-20 KR KR1020137029936A patent/KR20140037082A/ko not_active Withdrawn
- 2012-04-20 US US14/113,360 patent/US20140186326A1/en not_active Abandoned
- 2012-04-20 AU AU2012245280A patent/AU2012245280A1/en not_active Abandoned
- 2012-04-20 MX MX2013012345A patent/MX2013012345A/es not_active Application Discontinuation
- 2012-04-20 WO PCT/US2012/034479 patent/WO2012145644A1/en not_active Ceased
- 2012-04-20 EP EP12717025.6A patent/EP2699676A1/en not_active Withdrawn
-
2013
- 2013-10-14 IL IL228871A patent/IL228871A0/en unknown
- 2013-10-16 NI NI201300110A patent/NI201300110A/es unknown
- 2013-10-16 ZA ZA2013/07696A patent/ZA201307696B/en unknown
- 2013-10-17 CL CL2013003010A patent/CL2013003010A1/es unknown
- 2013-10-18 GT GT201300252A patent/GT201300252A/es unknown
- 2013-10-18 TN TNP2013000427A patent/TN2013000427A1/fr unknown
- 2013-10-29 CR CR20130555A patent/CR20130555A/es unknown
- 2013-11-14 MA MA36431A patent/MA35125B1/fr unknown
- 2013-11-20 CO CO13272849A patent/CO6811810A2/es not_active Application Discontinuation
- 2013-11-21 EC ECSP13013036 patent/ECSP13013036A/es unknown
-
2016
- 2016-09-23 JP JP2016185075A patent/JP2017035091A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| GT201300252A (es) | 2015-02-09 |
| IL228871A0 (en) | 2013-12-31 |
| CA2833371A1 (en) | 2012-10-26 |
| US20140186326A1 (en) | 2014-07-03 |
| JP2014513952A (ja) | 2014-06-19 |
| ECSP13013036A (es) | 2015-04-30 |
| CN103797115A (zh) | 2014-05-14 |
| EP2699676A1 (en) | 2014-02-26 |
| PH12013502149A1 (en) | 2019-09-02 |
| CO6811810A2 (es) | 2013-12-16 |
| WO2012145644A1 (en) | 2012-10-26 |
| CR20130555A (es) | 2013-12-09 |
| AU2012245280A1 (en) | 2013-11-07 |
| PE20140617A1 (es) | 2014-05-28 |
| TN2013000427A1 (en) | 2015-03-30 |
| SG194486A1 (en) | 2013-12-30 |
| BR112013026976A2 (pt) | 2019-09-24 |
| JP2017035091A (ja) | 2017-02-16 |
| KR20140037082A (ko) | 2014-03-26 |
| RU2013151875A (ru) | 2015-05-27 |
| ZA201307696B (en) | 2014-07-30 |
| MX2013012345A (es) | 2015-05-07 |
| SG10201605874TA (en) | 2016-09-29 |
| CL2013003010A1 (es) | 2014-03-07 |
| NI201300110A (es) | 2014-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA35125B1 (fr) | Alpha glucosidase acide modifiee a traitement accelere | |
| MA38276B1 (fr) | Dérivés de l'exendine 4 pour l’utilisation dans le traitement des troubles du syndrome metabolique, y compris le diabete et l'obesite, ainsi que la reduction de l'apport alimentaire excessif. | |
| TN2019000099A1 (en) | Anti-lag-3 antibodies and compositions | |
| PH12013501089A1 (en) | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by lp - pla2 | |
| MA34765B1 (fr) | Antagonistes des récepteurs de l'acide lysophosphatidique et utilisations de ceux-ci | |
| BR112013030894A2 (pt) | moduladores do sistema imune | |
| MA39211A1 (fr) | Composés tricycliques comme agents anti-cancers | |
| BR112014000380A2 (pt) | composição farmacêutica, métodos para tratamento e usos dos mesmos | |
| MA39033A1 (fr) | Formes solides d'acide {[5-(3-chlorophényl)-3-hydroxypyridine-2-carbonyl] amino}acétique, compositions et leurs utilisations | |
| EP2418945A4 (en) | Mineral salt-sulfuric acid compositions and methods for their use | |
| BR112013026114A2 (pt) | composições nutricionais que incluem ácidos graxos de cadeia ramificada e processos de utilização das mesmas | |
| MA35039B1 (fr) | Dérivés ramifiés de l'acide 3-phénylpropionique et leur utilisation | |
| MA35365B1 (fr) | Pyrimidines annelées substituées et leur utilisation | |
| BR112014032699A2 (pt) | métodos de tratamento de síndrome metabólica pediátrica | |
| MA33299B1 (fr) | Nouvelle formulation de naproxène | |
| MA35458B1 (fr) | Variants du facteur de croissance des fibroblastes 21 | |
| BR112014027571A2 (pt) | métodos para o tratamento de retinopatia diabética e outras doenças oftalmológicas | |
| BR112015007616A2 (pt) | inibidores de mek no tratamento de doenças por vírus | |
| MA45504A1 (fr) | Utilisation d'inhibiteurs de télomérase pour le traitement de troubles myéloprolifératifs et de néoplasies myéloprolifératives | |
| MA33295B1 (fr) | Nouvelle formulation de diclofénac | |
| MA38349A1 (fr) | Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3) | |
| BR112015010396A2 (pt) | terapia de combinação | |
| MX336715B (es) | Purificacion de iduronato-2-sulfatasa. | |
| CR20150196A (es) | Moléculas de unión il-17a novedosas y usos médicos de las mismas | |
| MA38638A1 (fr) | Marqueurs pour troubles liés à la sphingomyélinase acide et leurs utilisations |